Corline Biomedical Future Growth

Future criteria checks 6/6

Corline Biomedical is forecast to grow earnings and revenue by 127.5% and 76.7% per annum respectively. EPS is expected to grow by 127.9% per annum. Return on equity is forecast to be 40.2% in 3 years.

Key information

127.5%

Earnings growth rate

127.9%

EPS growth rate

Pharmaceuticals earnings growth68.8%
Revenue growth rate76.7%
Future return on equity40.2%
Analyst coverage

Low

Last updated03 May 2024

Recent future growth updates

Recent updates

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Aug 24
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Mar 15
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Nov 26
We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Jun 22
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Feb 16
We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

Jun 14
Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Feb 28
Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Earnings and Revenue Growth Forecasts

OM:CLBIO - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202618111391991
12/31/2025602014211
12/31/202436-11-21-141
6/30/202429-6-92N/A
3/31/202431-4-37N/A
12/31/202336-2-101N/A
9/30/202337-1-12-2N/A
6/30/2023401-120N/A
3/31/2023384-16-5N/A
12/31/2022332-15-6N/A
9/30/2022311-14-2N/A
6/30/202223-3-15-6N/A
3/31/202219-6-16-6N/A
12/31/202117-7-14-5N/A
9/30/202115-6-12-6N/A
6/30/202113-6-12-7N/A
3/31/202114-6-12-6N/A
12/31/202015-7-14-5N/A
9/30/202014-9-20-7N/A
6/30/202014-9-20-9N/A
3/31/202014-9-20-11N/A
12/31/201912-10-19-14N/A
9/30/201911-9-17-17N/A
6/30/201911-9-5-5N/A
3/31/201910-8-5-4N/A
12/31/201810-7-5-4N/A
9/30/201817-7-8-6N/A
6/30/201816-6-18-15N/A
3/31/201815-7N/A-16N/A
12/31/201716-8N/A-5N/A
9/30/20177-8N/A-2N/A
6/30/20179-8N/A-2N/A
3/31/201710-6N/A1N/A
12/31/20169-5N/A-7N/A
9/30/20168-6N/A-5N/A
6/30/20167-6N/A-4N/A
3/31/20165-7N/A-5N/A
12/31/20154-6N/A-4N/A
12/31/20144-3N/A-2N/A
12/31/20134-2N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).

Earnings vs Market: CLBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CLBIO is expected to become profitable in the next 3 years.

Revenue vs Market: CLBIO's revenue (76.7% per year) is forecast to grow faster than the Swedish market (1.1% per year).

High Growth Revenue: CLBIO's revenue (76.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CLBIO's Return on Equity is forecast to be very high in 3 years time (40.2%).


Discover growth companies